At a glance
ClinicalIndex Comparison RecordN/ACompleted· 47 enrolled
Drug / intervention
Forma Eye Applicatordevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Evaluation of Safety and Efficacy of Radio Frequency (Forma Eye) Treatment for Dry Eye Disease Due to Meibomian Gland Dysfunction
In Brief
A clinical study evaluating Forma Eye Applicator for Improvement of Dry Eye Disease. Completed, enrolled 47 participants across 3 sites.
Detailed Summary
The aim of the study is to evaluate the safety and efficacy of radiofrequency treatment for dry eye disease due to meibomian gland dysfunction
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImprovement of Dry Eye Disease
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
First PostedOct 2019
Enrollment StartOct 2019
Primary CompletionJul 2022
TodayJul 2026
First PostedOct 9, 2019
Enrollment StartOct 22, 2019
Primary CompletionJul 25, 2022
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 6.7 years ago
Interventions
Forma Eye Applicatordevice
Eligible subjects will receive up to 3 treatments (2-3 weeks interval) with the Forma Eye Applicator according to the study protocol. The subject will return for 3 follow up visits: four weeks (4wk FU), 12 weeks (12wk FU), twenty-four weeks (24wk FU) after the last treatment.